Here is a clinical trials update from December 2009 written by Jim Hughes United States RAD001 in combination with CP- 751,871 in patients with advanced sarcomas and other malignant neoplasms (NCT00927966) An mTOR inhibitor (RAD001) and [...]
You sit alone in a dreary doctor’s office; evidence of his medical expertise and importance adorn the walls. Maybe you sit there with a loved one, equally as scared and unprepared as you. The doctor hands you a verdict that says your time is up. Well now what do you do?
An interesting Phase 2 REGISTER study is ongoing and actively recruiting at 15 sites in Australia. Two sites in New Zealand and two sites in South Korea are also planned.
Neva Hatten Hageman, passed away Wednesday (08/12/09) at The Ambassador in Nebraska City. She was born to George and Ruth (Kempf) Calkins, at home on the family farm, Northwest of McCook, in Hayes County. Those [...]
This poster reported the latest data from the GIST ReGISTry, an online database of GIST patient statistics maintained by a group of American and Canadian GIST specialists and supported by Novartis Pharmaceuticals.
Four GIST patients have entered this Phase 1 trial of PI3K inhibitor SF1126.
In a January New York Times article, “Should Patients Be Told of Better Care Elsewhere,” the author, Denise Grady, discusses a friend who was diagnosed with rectal cancer and needed surgery, radiation and chemotherapy. The friend consulted [...]
The following article was reprinted from an email alert sent by LegisLink Action Center, a community education service of US Oncology. On September 16, the Centers for Medicare & Medicaid Services (CMS) broadened the scope [...]
Pat George, LRG member and volunteer is well-known in the community. Pat recently took it upon himself to help educate the local students
This article explains hereditary GIST. Familial cancer syndrome is a genetic condition that causes an increased risk for specific types of cancers. Familial cancer syndromes account for only five to ten percent of all [...]
